Therapeutically exploiting non-oncogene addiction and defining genetic interactions for disease progression in a preclinical model of inflammation-dependent gastric tumourigenesis

点击翻译按钮获取中文摘要

Cancers of the stomach are often associated with chronic inflammation and represent a major health burden with little treatment options available. We propose to test whether drugs undergoing clinical testing for other diseases may have beneficial effects in a preclinical model of gastric cancer, and establish the genetic interaction required for gastric cancer progression. The study outcomes may highlight novel therapeutic opportunities for the clinic.